Marked Increase of Venlafaxine Enantiomer Concentrations as a Consequence of Metabolic Interactions: A Case Report

On three occasions, unusually high trough plasma concentrations of venlafaxine were measured in a patient phenotyped and genotyped as being an extensive CYP2D6 metabolizer and receiving 450 mg/day of venlafaxine and multiple comedications. Values of 1.54 and of 0.60 mg/l of venlafaxine and O-desmethylvenlafaxine, respectively, were determined in the first blood sample, giving an unusually high venlafaxine to O-desmethylvenlafaxine ratio. This suggests an impaired metabolism of venlafaxine to O-desmethylvenlafaxine, and is most likely due to metabolic interactions with mianserin (240 mg/day) and propranolol (40 mg/day). Concentration of (S)-venlafaxine measured in this blood sample was almost twice as high as (R)-venlafaxine ((S)/(R) ratio: 1.94). At the second blood sampling, after addition of thioridazine (260 mg/day), which is a strong CYP2D6 inhibitor, concentrations of venlafaxine were further increased (2.76 mg/l), and concentrations of O-desmethylvenlafaxine decreased (0.22 mg/l). A decrease of the (S)/(R)-venlafaxine ratio (− 20 %) suggests a possible stereoselectivity towards the (R)-enantiomer of the enzyme(s) involved in venlafaxine O-demethylation at these high venlafaxine concentrations. At the third blood sampling, after interruption of thioridazine, concentrations of venlafaxine and O-desmethylvenlafaxine were similar to those measured in the first blood sample. This case report shows the importance of performing studies on the effects of either genetically determined or acquired deficiency of metabolism on the kinetics of venlafaxine.

References

• 1 Andersson T, Miners J O, Veronese M E, Birkett D J. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.  Br. J. Clin. Pharmacol.. 1994;  38 131-7
• 2 Baumann P, Meyer J W, Amey N, Baettig D, Bryois C, Jonzier-Perey M, Koeb L, Monney C, Woggon B. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline.  Ther. Drug. Monit.. 1992;  14 1-8
• 3 Bertilsson L, Henthorn T K, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenitoin, but not debrisoquin, hydroxylation phenotype.  Clin. Pharmacol. Ther.. 1989;  45 348-355
• 4 Dahl M-L, Tybring G, Elwin C-E, Alm C, Andreasson K, Gyllenpalm M, Bertilsson L. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.  Clin. Pharmacol. Ther.. 1994;  56 176-183
• 5 Eap C B, Guentert T W, Schäublin-Loidl M, Stabl M, Koeb L, Powell K, Baumann P. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.  Clin. Pharmacol. Ther.. 1996;  59 322-331
• 6 Eap C B, de Mendoca F, Woggon B, Powell K, Baumann P. Steady- state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine.  Ther. Drug. Monit.. 1998;  20 7-13
• 7 Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine.  J. Clin. Psychopharmacol.. 1996;  16 (suppl. 2) 37
• 8 Griese E-U, Zanger U M, Brudermanns U, Gaedigk A, Mikus G, Mörike K. et al . Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.  Pharmacogenetics.. 1998;  8 15-26
• 9 Heim M, Meyer U A. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.  Lancet.. 1990;  336 -532
• 10 Holliday S M, Benfield P. Venlafaxine: A review of its pharmacology and therapeutic potential in depression.  Drugs.. 1995;  49 280-294
• 11 Klamerus K J, Maloney K, Rudolph R L, Sisenwine S F, Jusko W J, Chiang S T. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite.  J. Clin. Pharmacol.. 1992;  32 716-724
• 12 Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers.  J. Pharmacol. Exp. Ther.. 1996;  278 21-30
• 13 Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes - The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.  Drug. Metab. Dispos.. 1994;  22 909-915
• 14 Murray M, Reidy G F. In vitro inhibition of hepatic drug oxidation by thioridazine.  Biochem. Pharmacol.. 1989;  38 4359-4365
• 15 Otton S V, Gillam E M, Lennard M S, Tucker G T, Woods H F. Propranolol oxidation by human liver microsomes - the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.  Br. J. Clin. Pharmacol.. 1990;  30 751-760
• 16 Otton S V, Ball S E, Cheung S M, Inaba T, Rudolph R L, Sellers E M. Venlafaxine oxidation in vitro is catalysed by CYP2D6.  Br. J. Clin. Pharmacol.. 1996;  41 149-156
• 17 Rowland K, Yeo W W, Ellis S W, Chadwick I G, Haq I, Lennard M S, Jackson P R, Ramsay L E, Tucker G T. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.  Br. J. Clin. Pharmacol.. 1994;  38 9-14
• 18 Souery D, Amsterdam J, De Montigny C, Lecrubier Y, Montgomery S, Lipp O. et al . Treatment resistant depression: methodological overview and operational criteria.  Eur. Neuropsychopharmacol.. 1999;  9 83-91
• 19 Spina E, Buemi A L, Sanz E, Bertilsson L. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.  Ther. Drug. Monit.. 1989;  11 721-723
• 20 von Bahr C, Movin G, Nordin C, Liden A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjöqvist F. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.  Clin. Pharmacol. Ther.. 1991;  49 234-240
• 21 Wang C P, Howell S R, Scatina J, Sisenwine S F. The disposition of venlafaxine enantiomers in dogs, rats and humans receiving venlafaxine.  Chirality.. 1992;  4 84-90
• 22 Yasumori T, Nagata Y, Yang S K, Chen L-S, Murayama N, Yamazoe Y, Kato R. Cytochrome-P450 mediated metabolism of diazepam in human and rat - involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner.  Pharmacogenetics.. 1993;  3 291-301
• 23 Zhou H H, Anthony L B, Roden D M, Wood A JJ. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation.  Clin. Pharmacol. Ther.. 1990;  47 686-693